Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Antioxidant and antibacterial properties of transition metals and metal oxides for medical uses: mechanisms, design strategies, and biomedical perspectives

Iman A. Mohammed Alia and Ali Ben Ahmed*b
aMinistry of Higher Education and Scientific Research, Baghdad, Iraq
bUniversity of Sfax, Higher Institute of Biotechnology of Sfax, Sfax, Tunisia. E-mail: ali.benahmed@isbs.usf.tn

Received 25th April 2026 , Accepted 24th May 2026

First published on 3rd June 2026


Abstract

This review provides a critical and integrative analysis of transition metal and metal oxide NPs as emerging multifunctional platforms for biomedical applications, with particular emphasis on their dual antioxidant and antibacterial properties. Beyond conventional descriptive approaches, we systematically correlate physicochemical parameters, including particle size, morphology, surface charge, crystallinity, and functionalization, with biological performance, thereby establishing clear structure–activity relationships governing therapeutic efficacy and biosafety. Key transition metals such as Ag, Cu, Se, Ti, Zn, and Fe, along with their oxides, are examined in terms of their mechanistic pathways, including reactive oxygen species (ROS) modulation, metal ion release, membrane disruption, and enzyme-mimetic antioxidant activity. Recent advances in synthesis strategies, particularly green and bioinspired methods, are highlighted as enabling routes for improving biocompatibility, stability, and targeted functionality. Importantly, this review critically discusses the dual role of ROS in mediating both antibacterial action and oxidative stress regulation, offering a unified framework for designing balanced nano-therapeutics. Comparative analyses reveal that materials with strong antibacterial activity often exhibit weaker intrinsic antioxidant capacity, underscoring the need for rational design of hybrid or multifunctional nanoplatforms. Furthermore, key challenges related to cytotoxicity, long-term biosafety, microbial resistance, and clinical translation are comprehensively evaluated. Strategies such as surface engineering, controlled ion release, and synergistic combinations with conventional antibiotics are proposed to overcome these limitations. By bridging fundamental mechanisms with applied biomedical perspectives, this review provides actionable insights for the next generation of safe, effective, and clinically translatable metal-based nanomaterials.


1 Introduction

The rapid emergence of antibiotic-resistant microorganisms and the increasing prevalence of oxidative stress-related diseases represent major challenges for modern medicine, and create an urgent need for innovative therapeutic strategies. Conventional antimicrobial agents are progressively losing efficacy, prompting the search for alternative therapeutic strategies capable of combating resistant pathogens while minimizing adverse effects.1–3 Similarly, oxidative stress has been implicated in numerous pathological conditions, including cancer, neurodegenerative disorders, cardiovascular diseases, and chronic inflammation.4,5 In this context, transition metals and their oxide nanomaterials have emerged as promising candidates for biomedical applications due to their unique physicochemical and catalytic properties including antimicrobial therapy and oxidative stress regulation (see Fig. 1).
image file: d6na00329j-f1.tif
Fig. 1 Overview of transition metal and metal oxide NPs used in biomedical applications.

Nanotechnology has emerged as a powerful platform for the development of advanced biomedical materials capable of addressing these challenges. In particular, transition metal and metal oxide NPs have demonstrated exceptional potential due to their unique physicochemical characteristics, including high surface-area-to-volume ratio, tunable electronic properties, and catalytic activity.6,7 Metals such as silver (Ag), copper (Cu), iron (Fe), titanium (Ti), and selenium (Se) exhibit intrinsic antimicrobial and antioxidant properties. When engineered at the nanoscale, these materials display enhanced biological activity resulting from increased surface reactivity and improved interaction with microbial cells.8,9

Transition metal NPs and their oxides exert antibacterial effects through multiple mechanisms, including generation of reactive oxygen species (ROS), release of metal ions, disruption of bacterial membranes, interference with cellular metabolism.10 In addition to their antimicrobial effects, several metal-based nanomaterials demonstrate significant antioxidant capabilities by scavenging free radicals, mimicking antioxidant enzymes,11 and regulating intracellular redox balance.12,13 Silver (Ag) and its oxide (AgO) have long been recognized for their strong bactericidal properties,14 while selenium (Se and SeO2) exhibits potent antioxidant activity through redox cycling and glutathione peroxidase mimicry.15,16 Copper (Cu and CuO) combines both antibacterial and pro-oxidant properties, useful for wound healing and biofilm inhibition,17–21 whereas titanium-based materials (Ti, TiO2) are extensively applied in medical implants with excellent antibacterial coatings and photocatalytic ROS generation.22,23

Transition metals possess partially filled d-orbitals that allow them to participate in redox reactions, electron transfer processes, and catalytic transformations. These characteristics enable metal-based nanomaterials to interact with biological systems through mechanisms such as reactive oxygen species (ROS) modulation, metal ion release, and surface catalytic reactions. Consequently, NPs composed of metals such as Ag, Cu, Zn, Fe, Se, Au, and Ti have demonstrated significant antimicrobial and antioxidant activities.24,25

In addition to their intrinsic redox properties, the biological performance of these materials strongly depends on several physicochemical parameters, including particle size, morphology, crystallinity, surface charge, and chemical functionalization. NPs typically exhibit higher surface-to-volume ratios compared with bulk materials, which enhances their catalytic activity, ion release, and interaction with microbial membranes. These factors collectively influence both therapeutic efficacy and potential cytotoxicity.26

Recent advances in nanotechnology have enabled precise control over nanoparticle synthesis and surface engineering. Techniques such as green synthesis, polymer functionalization, and ligand-mediated targeting allow researchers to design nanomaterials with improved stability, biocompatibility, and therapeutic performance.27 Furthermore, multifunctional nanoplatforms capable of combining antimicrobial, antioxidant, and drug-delivery functions are increasingly being explored.

Despite these promising developments, several challenges remain before metal-based nanomaterials can be widely implemented in clinical applications. Concerns related to toxicity, long-term stability, bioaccumulation, and environmental impact require careful evaluation. In addition, regulatory approval of nanomaterials for medical use demands rigorous characterization, reproducibility, and biosafety assessment.28,29

This review aims to provide a comprehensive overview of transition metal and metal oxide NPs used in biomedical applications, focusing on their antibacterial and antioxidant properties, synthesis strategies, mechanisms of action, toxicity considerations, and future perspectives. We focus on their synthesis strategies, physicochemical properties, mechanisms of antibacterial and antioxidant activity, and emerging biomedical applications. Furthermore, we discuss key challenges related to toxicity, microbial resistance, and clinical translation, and propose future research directions to optimize the balance between efficacy, safety, and sustainability.30,31

2 Synthesis strategies for metal and metal oxide NPs

The synthesis method significantly influences nanoparticle structure, stability, and biomedical performance. The Fig. 2 present several physical, chemical, and biological methods have been developed to synthesize metal NPs with controlled size and morphology.
image file: d6na00329j-f2.tif
Fig. 2 Common synthesis routes for metal and metal oxide NPs.

Recent studies focus on green synthesis using plant extracts, biopolymers, and amino acids to enhance biocompatibility and reduce cytotoxicity. Surface functionalization with ligands, polymers, or peptides improves targeting and stability in physiological environments.32–35

By leveraging natural resources and advanced functionalization processes, researchers are striving to create safer and more effective materials for medical use, which could significantly benefit drug delivery systems, tissue engineering, and diagnostics.36–38

The process of modifying material surfaces with ligands or peptides enhances specific applications, such as targeting tumor cells. Enhanced targeting means more effective delivery of drugs to specific cells, increasing treatment efficiency. Improved stability in physiological conditions ensures that the materials perform consistently in complex biological systems.

The focus on biocompatibility is crucial for advancing medical technologies. As personalized medicine evolves, the need for materials that can safely interact with the human body without causing adverse effects becomes ever more pressing. The advancements cited in the article can lead to enhanced therapeutic options and improved patient outcomes. The incorporation of advanced functionalization techniques allows for innovations in targeted therapies.39–41 The ability to modify surfaces at the molecular level opens the door to new methodologies in drug delivery where precision is crucial. This could lead to more effective treatments with reduced side effects.42

Coupled with innovative surface functionalization techniques, these developments point to a future where medical materials can be optimized for safety and efficiency. As research continues to evolve in this domain, it holds the promise of smarter, environmentally friendly solutions that can transform healthcare delivery and improve patient outcomes.

Various synthesis techniques have been developed to produce metal and metal oxide NPs with controlled size, morphology, and surface characteristics. These approaches can generally be classified into three major categories.43

2.1 Chemical synthesis

Chemical reduction methods are widely used for the preparation of metal NPs due to their simplicity and scalability. Reducing agents such as sodium borohydride, hydrazine, and citrate are commonly employed to convert metal ions into metallic NPs. While chemical synthesis provides precise control over particle characteristics, it may involve toxic reagents and generate environmentally hazardous by-products.44,45

2.2 Physical synthesis

Physical techniques include laser ablation, evaporation–condensation, vapor deposition and mechanical milling. These methods typically produce highly pure NPs but often require expensive equipment and high energy consumption, limiting large-scale production.3,4

2.3 Green synthesis

Green synthesis has emerged as an environmentally friendly alternative that utilizes biological systems such as plant extracts, bacteria, fungi, and algae. Biomolecules present in these systems act as both reducing and stabilizing agents, enabling the formation of NPs without toxic chemicals. Green synthesis approaches offer several advantages reduced environmental impact, improved biocompatibility and lower energy consumption. Nevertheless, challenges remain regarding reproducibility and scalability, which must be addressed before industrial implementation.5,46

3 Physicochemical parameters influencing bioactivity

The biological performance of metal NPs is strongly influenced by their physicochemical properties. Parameters such as particle size, morphology, surface charge, crystallinity, and chemical composition determine how NPs interact with biological systems. Overall, rational engineering of nanoparticle physicochemical parameters provides an effective strategy to optimize antimicrobial and antioxidant performance while minimizing adverse biological effects.

3.1 Particle size and surface area

Particle size significantly affects nanoparticle–cell interactions. Smaller NPs possess larger surface area relative to volume, enabling stronger interactions with bacterial membranes and enhanced catalytic activity. NPs smaller than 50 nm typically demonstrate improved antibacterial performance due to their ability to penetrate microbial cell walls and generate reactive oxygen species more efficiently. Smaller NPs possess larger surface-to-volume ratios, which enhance catalytic activity and facilitate interactions with microbial cell membranes.47

As a result, nanoscale particles often exhibit significantly higher antimicrobial efficiency compared with their bulk counterparts. However, reduced particle size may also increase cytotoxicity and cellular uptake, potentially leading to undesirable effects in healthy tissues. Therefore, optimizing nanoparticle size is essential to balance therapeutic efficacy and biosafety.48

3.2 Morphology and crystal structure

Nanoparticle shape also plays an important role in determining biological activity. Rod-shaped, star-shaped, and sheet-like NPs often exhibit enhanced interactions with microbial membranes compared with spherical particles due to their anisotropic surface structures.5 The Fig. 3 provide the physicochemical characteristics of NPs, including size, morphology, and surface charge, strongly influence their biological activity. Nanoparticle morphology, including spherical, rod-like, cubic, or flower-like structures, influences their surface reactivity and interaction with biological molecules.
image file: d6na00329j-f3.tif
Fig. 3 Influence of nanoparticle size, morphology, and surface properties on biological activity.

For example, rod-shaped NPs often display enhanced membrane penetration capabilities, whereas highly faceted crystalline structures may expose reactive catalytic sites.49

Crystal structure also affects electron transfer processes and redox behavior, which are critical for ROS generation and antioxidant activity. Surface charge influences electrostatic interactions with bacterial cells. Since bacterial membranes are typically negatively charged, positively charged NPs display stronger adhesion and improved antibacterial effects.50

Morphology and crystal structure also affect biological interactions. For example, rod-shaped NPs often exhibit stronger membrane interactions compared with spherical particles due to anisotropic surface energy distribution. Similarly, crystal facets in materials such as TiO2 and ZnO can influence photocatalytic ROS production and thus antimicrobial efficiency.51

3.3 Surface charge and functionalization

Surface modification strategies such as polymer coating, ligand attachment, or biomolecule conjugation can significantly improve nanoparticle stability and biocompatibility. Examples include PEGylation, chitosan coating and antibody conjugation. These strategies enhance nanoparticle dispersion, reduce aggregation, and enable targeted delivery.12

Surface charge plays a key role in nanoparticle–cell interactions. Positively charged NPs tend to interact more strongly with negatively charged bacterial membranes, enhancing antimicrobial activity. Surface functionalization with polymers, peptides, or biomolecules can further improve nanoparticle stability and targeting ability.

Common functionalization strategies include polymer coatings (PEG, chitosan), peptide or antibody conjugation, biomolecule immobilization and ligand-based targeting systems. These modifications can improve biocompatibility, prevent aggregation, and enable targeted drug delivery.

Surface charge plays a crucial role in nanoparticle–cell interactions. Positively charged NPs tend to exhibit stronger antibacterial effects because bacterial membranes are generally negatively charged, promoting electrostatic attraction and membrane disruption.

Surface functionalization with polymers, peptides, or biomolecules can significantly improve nanoparticle stability and targeting ability. Functionalization strategies such as PEGylation, chitosan coating, or antibody conjugation enhance colloidal stability, reduce nonspecific toxicity, and enable targeted delivery to infected tissues.13

4 Antibacterial mechanisms of metal and metal oxide NPs

Metal NPs exert antibacterial activity through multiple mechanisms. Metal NPs exert antibacterial activity through multiple mechanisms including ROS generation, membrane disruption, and interference with intracellular processes (see Fig. 4).
image file: d6na00329j-f4.tif
Fig. 4 Schematic representation of antibacterial mechanisms of metal NPs.

4.1 Reactive oxygen species generation

One of the primary mechanisms involves the generation of reactive oxygen species (ROS), including superoxide radicals, hydroxyl radicals and hydrogen peroxide.6 These ROS species damage bacterial membranes, proteins, and nucleic acids. Metal-based NPs exhibit antimicrobial activity through several complementary mechanisms.

Many metal oxide NPs, including TiO2, ZnO, and CuO, can generate reactive oxygen species under physiological conditions or light irradiation.7,9,24 ROS such as superoxide radicals, hydroxyl radicals, and hydrogen peroxide cause oxidative damage to bacterial membranes, proteins, and DNA. The antioxidant activity of NPs involves several ROS scavenging pathways (see Fig. 5).


image file: d6na00329j-f5.tif
Fig. 5 ROS scavenging pathways in nanoparticle antioxidant activity.

4.2 Membrane disruption

Direct physical interaction between NPs and bacterial membranes can lead to structural damage, increased permeability, and leakage of intracellular components.26 Metal NPs can directly interact with bacterial membranes, leading to membrane permeability changes, leakage of cellular components and structural damage. As can be see Fig. 6, NPs can penetrate biofilms and disrupt microbial communication and metabolic pathways.27
image file: d6na00329j-f6.tif
Fig. 6 Interaction of NPs with bacterial biofilms.

4.3 Metal ion release

Metal ions released from NPs, including Ag+, Cu2+, and Zn2+, interact with bacterial enzymes and nucleic acids. These ions disrupt metabolic pathways, inhibit enzyme activity, and interfere with DNA replication.25,48

4.4 DNA and protein damage

Metal ions and NPs may bind to thiol groups in proteins and nucleic acids, leading to enzyme inactivation and inhibition of cellular functions. The combination of these mechanisms makes metal-based NPs highly effective antimicrobial agents with reduced susceptibility to traditional resistance pathways.30

5 Antioxidant mechanisms

In addition to antimicrobial activity, several metal oxide NPs exhibit antioxidant properties. CeO2 NPs are particularly notable due to their ability to cycle between Ce3+ and Ce4+ oxidation states. This redox cycling allows them to mimic natural antioxidant enzymes such as superoxide dismutase and catalase, enabling efficient scavenging of reactive oxygen species.8 Similarly, ZnO and Fe3O4 NPs can modulate oxidative stress through catalytic reactions that neutralize free radicals. These properties make them attractive candidates for treating diseases associated with oxidative damage. Some metal oxide NPs exhibit enzyme-like antioxidant properties capable of scavenging reactive oxygen species (see Fig. 7).
image file: d6na00329j-f7.tif
Fig. 7 Antioxidant mechanisms of metal NPs.

5.1 Free radical scavenging

Certain NPs neutralize reactive oxygen species by donating electrons or hydrogen atoms.6

5.2 Enzyme-mimetic activity

Some NPs mimic natural antioxidant enzymes such as superoxide dismutase, catalase, and peroxidase.31

5.3 Redox cycling

Metals such as selenium participate in redox cycling reactions that help maintain cellular redox balance.42

6 Comparative properties of metal NPs

To better illustrate the diversity and biomedical potential of transition metal and metal oxide NPs, a comparative overview of their physicochemical characteristics and biological activities is presented in Table 1.
Table 1 Comparative physicochemical properties and biomedical activities of transition metal and metal oxide NPs
NPs Size (nm) Properties Antibacterial mechanism Antioxidant mechanism Biomedical applications Limitations
Ag 5–100 High electrical conductivity, strong ion release (Ag+), high surface reactivity Membrane disruption, Ag+ ion release, ROS generation, DNA interaction Weak intrinsic antioxidant activity Wound dressings, antimicrobial coatings, medical devices Cytotoxicity at high concentrations
ZnO 10–200 Wide band gap semiconductor, strong photocatalytic activity ROS production, Zn2+ ion release, membrane penetration Moderate radical scavenging Antibacterial coatings, drug delivery, biosensors Phototoxicity under UV
CuO 10–150 Redox-active surface, Fenton-like catalytic activity ROS generation, lipid peroxidation, Cu2+ ion release Moderate antioxidant properties Antimicrobial surfaces, wound healing Potential oxidative cytotoxicity
TiO2 10–200 Photocatalytic semiconductor, high chemical stability ROS generation under UV/visible light, membrane damage ROS modulation under controlled conditions Implant coatings, photodynamic therapy Limited activity without light
CeO2 5–50 Ce3+/Ce4+ redox cycling, oxygen vacancy defects Moderate antibacterial activity via membrane interaction Strong antioxidant (SOD/CAT mimetic activity) Neuroprotection, anti-inflammatory therapies Lower direct antimicrobial activity
Fe3O4 10–100 Magnetic properties, good biocompatibility ROS generation under magnetic stimulation Moderate antioxidant activity Drug delivery, MRI contrast agents Limited intrinsic antimicrobial activity
Se 20–150 Redox-active element, high biological compatibility ROS modulation, metabolic inhibition Strong antioxidant activity via glutathione pathways Antioxidant therapies, anticancer research Narrow therapeutic window
Au 5–100 High stability, tunable surface chemistry Membrane interaction and enzyme inhibition Limited antioxidant activity unless functionalized Drug delivery, biosensing, imaging High cost


These nanomaterials exhibit distinct properties depending on their chemical composition, particle size, morphology, and surface characteristics, which collectively influence their interaction with biological systems. In particular, metals such as silver, copper, zinc, iron, and selenium, as well as their corresponding oxides, have demonstrated significant antibacterial and antioxidant capabilities through mechanisms including reactive oxygen species (ROS) generation, membrane disruption, metal ion release, and enzyme-mimetic activity. By summarizing key parameters such as nanoparticle composition, typical size range, dominant mechanisms of action, and representative biomedical applications, this table provides a concise comparison that highlights both the similarities and unique advantages of different metal-based nanomaterials in antimicrobial and antioxidant therapies.

While Table 1 provides a comparative overview of the physicochemical characteristics and general biomedical functions of major transition metal and metal oxide NPs, a deeper understanding of their practical applications also requires examining how these materials are synthesized and engineered. In recent years, significant progress has been made in developing controlled synthesis strategies that allow precise tuning of nanoparticle size, morphology, and surface properties, which are critical parameters governing their biological performance. Consequently, a more detailed comparison of representative nanomaterials reported in recent studies is presented in Table 2, focusing on their synthesis methods, particle size ranges, and experimentally observed antibacterial or antioxidant activities.

Table 2 Comparison of representative transition metal and metal oxide NPs used in biomedical applications, highlighting their synthesis approaches, particle size ranges, and dominant antibacterial or antioxidant mechanisms
NPs Synthesis method Size (nm) Target microorganisms Biological activity Ref.
Ag Chemical reduction 10–40 E. coli, S. aureus Strong antibacterial activity via membrane disruption and ROS generation 26 and 49
CuO Sol–gel method 20–50 Gram-positive and Gram-negative bacteria Metal ion release and oxidative stress induction 3 and 51
ZnO Hydrothermal synthesis 30–80 E. coli, P. aeruginosa ROS generation and photocatalytic antibacterial activity 4, 5 and 51
TiO2 Sol–gel/hydrothermal 15–60 Bacterial biofilms Photocatalytic ROS production under UV irradiation 7, 43 and 51
Fe3O4 Co-precipitation 20–40 Drug delivery systems Antioxidant enzyme-mimetic activity 5 and 48
Se Green synthesis (plant extracts) 50–100 Oxidative stress models Strong antioxidant and radical scavenging activity 5 and 46
Au Citrate reduction 10–30 Cancer cells/bacterial systems Antibacterial and biosensing applications 9
Cu Chemical reduction 30–70 Multidrug-resistant bacteria ROS generation and protein oxidation 47
MnO2 Hydrothermal synthesis 40–90 Cellular oxidative stress models Catalase-like antioxidant activity 6
CeO2 Precipitation method 5–20 Inflammatory disease models Redox cycling between Ce3+/Ce4+ enabling antioxidant behavior 44


To further highlight recent developments in the biomedical application of metal-based nanomaterials, Table 2 summarizes representative transition metal and metal oxide NPs reported in recent studies, with emphasis on their synthesis approaches, particle size ranges, and corresponding biological activities. The synthesis strategy plays a crucial role in determining nanoparticle physicochemical properties such as size distribution, morphology, surface charge, and stability, which in turn influence their interaction with microbial cells and biological environments.

Various preparation methods, including chemical reduction, hydrothermal synthesis, sol–gel processes, co-precipitation, and green synthesis using biological extracts, have been widely employed to produce NPs with tailored characteristics. These engineered nanomaterials have demonstrated promising antibacterial and antioxidant performance against a wide range of microorganisms and oxidative stress models through mechanisms such as reactive oxygen species generation, membrane damage, and catalytic redox activity. The comparative overview provided in Table 2 therefore offers valuable insights into how synthesis methods and structural parameters influence the biomedical functionality of transition metal and metal oxide NPs.

As illustrated in Table 2, the biological performance of metal-based NPs is strongly influenced by their synthesis route and resulting structural characteristics. NPs produced through controlled methods such as hydrothermal synthesis, sol–gel processes, or green synthesis often exhibit enhanced stability and optimized size distributions, which contribute to improved antibacterial and antioxidant efficiency. In particular, smaller NPs generally demonstrate stronger antimicrobial activity due to their larger surface area and enhanced interaction with microbial membranes. Furthermore, certain metal oxide NPs such as CeO2, ZnO, and TiO2 display notable catalytic or redox properties that enable both ROS generation for antimicrobial action and ROS scavenging for antioxidant protection. These observations highlight the importance of rational nanoparticle design and synthesis optimization in maximizing the biomedical potential of transition metal nanomaterials.

7 Toxicity, biosafety, and biocompatibility considerations

Despite their promising biomedical applications, transition metal and metal oxide NPs raise important concerns regarding toxicity and long-term biosafety. Their small size and high surface reactivity can lead to unintended interactions with biological systems, potentially inducing oxidative stress, inflammation, and cellular damage.9 Despite their therapeutic potential, metal-based NPs may present toxicity risks depending on their physicochemical properties. Excessive ROS generation, uncontrolled ion release, and nanoparticle accumulation in tissues can lead to oxidative stress, inflammation, and cellular damage. Strategies to mitigate toxicity include surface functionalization, controlled ion release, targeted delivery systems and biodegradable coatings. Comprehensive toxicity studies, including in vitro and in vivo models, are essential to ensure safe biomedical applications.3

Major toxicity mechanisms include oxidative stress, inflammation, DNA damage and cellular apoptosis. NPs may accumulate in organs such as the liver, spleen, and lungs following systemic administration. To mitigate toxicity risks, researchers have explored several strategies surface functionalization, biodegradable coatings and controlled release systems. Comprehensive in vivo studies remain essential for evaluating long-term biosafety. Despite their promising biomedical potential, metal NPs may induce oxidative stress and cytotoxicity depending on their physicochemical properties (see Fig. 8).


image file: d6na00329j-f8.tif
Fig. 8 Cellular toxicity pathways induced by metal NPs.

One major toxicity mechanism involves excessive generation of reactive oxygen species, which can damage cellular proteins, lipids, and DNA. While ROS production contributes to antibacterial activity, uncontrolled oxidative stress may also affect healthy tissues. Therefore, balancing antimicrobial efficacy with biocompatibility remains a critical challenge.

The biodistribution and clearance of NPs depend on several factors, including size, surface charge, and surface functionalization. NPs smaller than approximately 10 nm may undergo rapid renal clearance, whereas larger particles may accumulate in organs such as the liver, spleen, and lungs through the reticuloendothelial system.6

Surface modification strategies have been widely explored to reduce toxicity and improve biocompatibility. For instance, coating NPs with biocompatible polymers such as polyethylene glycol (PEG), chitosan, or proteins can reduce aggregation, enhance stability in physiological environments, and mitigate nonspecific cellular interactions.

Furthermore, comprehensive in vivo studies remain limited, particularly regarding long-term exposure and potential bioaccumulation. Future research should focus on systematic toxicity assessments, standardized evaluation protocols, and the development of safer nanomaterial designs to facilitate clinical translation.

8 Microbial resistance and synergistic strategies

Although metal-based NPs exhibit broad-spectrum antimicrobial activity, the potential development of microbial resistance remains an important consideration.29 Unlike conventional antibiotics that typically target specific molecular pathways, metal NPs often act through multiple mechanisms, including ROS generation, metal ion release, and membrane disruption. This multi-target mode of action reduces the likelihood of rapid resistance development.

Nevertheless, adaptive responses in microorganisms have been reported, including increased expression of metal efflux pumps, biofilm formation, and enhanced antioxidant defense systems. Such mechanisms may reduce nanoparticle susceptibility over prolonged exposure.

To mitigate resistance development, several strategies have been proposed. One promising approach involves combining metal NPs with conventional antibiotics, which can produce synergistic antibacterial effects. For example, silver NPs combined with antibiotics such as ampicillin or tetracycline have demonstrated enhanced antibacterial efficacy against resistant bacterial strains.30,31

Another strategy involves designing multifunctional NPs incorporating multiple metal components (Ag–Cu or ZnO–TiO2 composites), which may enhance antimicrobial potency while reducing the required dosage.

Continued research into nanoparticle–microbe interactions is essential to better understand resistance mechanisms and develop more sustainable antimicrobial technologies. Combining NPs with antibiotics or designing multifunctional nanocomposites can reduce the likelihood of resistance and enhance antimicrobial efficacy.

The translation of nanomaterials into clinical applications requires rigorous evaluation of safety, reproducibility, and manufacturing standards. Regulatory agencies require detailed characterization of nanoparticle size distribution, chemical composition, and biological interactions. Challenges include large-scale manufacturing, long-term stability, regulatory approval and cost-effectiveness. Addressing these issues will be essential for successful clinical implementation.

9 Structure–activity relationships in metal-based nanomaterials

Understanding the relationship between nanoparticle structure and biological activity is essential for optimizing therapeutic performance. Structure–activity relationships (SAR) describe how variations in physicochemical properties influence biological interactions (see Fig. 9).
image file: d6na00329j-f9.tif
Fig. 9 Structure–activity relationship between nanoparticle size, morphology, surface charge, and biological activity.

9.1 Particle size: a dual determinant of bioavailability and toxicity

Particle size strongly affects antimicrobial efficiency and cellular uptake. Smaller NPs exhibit greater surface reactivity and enhanced ability to penetrate bacterial cell walls, thereby increasing antibacterial potency. However, excessively small particles may also increase toxicity toward mammalian cells.

Particle size is a primary determinant governing nanoparticle–biological interactions by simultaneously modulating cellular uptake, dissolution kinetics, and ROS generation. Nanoparticles below 20 nm typically exhibit enhanced cellular internalization due to endocytotic uptake pathways and increased surface reactivity. However, this same feature often leads to elevated cytotoxicity associated with uncontrolled ion release and oxidative stress.52

In metallic systems such as Ag and Cu nanoparticles, decreasing size significantly accelerates ion dissolution (Ag+, Cu2+), directly enhancing antimicrobial efficacy but also increasing non-selective toxicity toward mammalian cells.53 In contrast, metal oxide nanoparticles (e.g., ZnO, TiO2) exhibit size-dependent modulation of surface defect density and oxygen vacancy concentration, which directly influences photocatalytic ROS production rather than simple ion release. Thus, size regulation represents a trade-off between biological efficacy and biocompatibility, which is strongly material-dependent.54

9.2 Morphology and crystal facet engineering

Morphology also plays a critical role. Nanorods, nanosheets, and nanostars provide higher surface anisotropy compared with spherical NPs, enabling stronger interactions with microbial membranes and improved catalytic activity. As can be see Fig. 9, the structure–activity relationships provide valuable insights into how nanoparticle physicochemical properties influence antibacterial and antioxidant performance.55

Nanoparticle morphology governs the availability of active surface sites and the spatial distribution of reactive crystal facets. Anisotropic structures such as rods, stars, and plates exhibit higher antibacterial activity compared to spherical counterparts due to enhanced membrane contact points and localized electric field intensification at sharp edges. For example, ZnO nanorods and TiO2 nanoplates expose high-energy facets that favor electron transfer reactions and ROS generation under physiological or photoactivated conditions. Conversely, spherical nanoparticles tend to be more stable but less reactive due to lower surface defect density. This highlights that morphology does not merely influence geometry but directly dictates catalytic and biological reactivity.56

9.3 Surface charge and interfacial biointeractions

Surface charge critically regulates electrostatic interactions with bacterial membranes, which are typically negatively charged due to phospholipid and lipopolysaccharide content. Positively charged nanoparticles demonstrate enhanced bacterial adhesion and membrane disruption, leading to increased antimicrobial activity. However, this same property also promotes rapid opsonization and clearance by the mononuclear phagocyte system (MPS), reducing systemic circulation time. Neutral or PEGylated nanoparticles exhibit improved colloidal stability and reduced protein adsorption but often show weaker direct antimicrobial effects.57 Therefore, surface charge tuning represents a key parameter controlling the balance between bioactivity and systemic stability.

Surface charge determines electrostatic interactions with biological membranes. Positively charged NPs often demonstrate stronger antibacterial effects due to their enhanced affinity for negatively charged bacterial surfaces. Finally, surface functionalization significantly alters nanoparticle behavior in biological environments. Functional coatings can enhance stability, reduce aggregation, and improve targeting of specific tissues or pathogens.

By systematically tuning these structural parameters, it is possible to design metal-based nanomaterials with optimized antibacterial and antioxidant performance.58

9.4 Distinction between metallic and metal oxide nanoparticle systems

A critical distinction must be made between metallic nanoparticles (Ag, Cu, Au) and metal oxide systems (ZnO, TiO2, CeO2), as their biological mechanisms fundamentally differ. Metallic nanoparticles primarily exert antimicrobial activity through direct ion release (Ag+, Cu2+), membrane disruption, and thiol group binding in proteins. In contrast, metal oxides operate via ROS generation (photocatalytic or redox-driven), oxygen vacancy-mediated electron transfer, and enzyme-mimetic antioxidant activity (notably CeO2).59 For instance, CeO2 exhibits dual antioxidant/pro-oxidant behavior depending on Ce3+/Ce4+ ratio, making its biological response context-dependent, unlike Ag nanoparticles which are predominantly cytotoxic.60 This mechanistic divergence explains why similar physicochemical parameters may lead to drastically different biological outcomes across material classes.61

9.5 Integrated structure–activity framework

Overall, nanoparticle bioactivity cannot be attributed to a single parameter but arises from the interplay between size, morphology, surface charge, and material composition. These parameters collectively determine cellular uptake efficiency, ROS generation pathways, protein corona formation, and dissolution/ion release kinetics.62 A unified SAR model therefore requires simultaneous consideration of physicochemical and compositional variables rather than isolated descriptors.63,64

10 Transition metals in medical applications

10.1 Silver

Silver is a well-known antimicrobial agent, widely used in wound dressings, coatings for medical devices, and topical ointments. The antibacterial mechanism is disruption of bacterial cell membranes, interaction with thiol groups in enzymes and DNA, and induction of ROS generation leading to oxidative stress. For the applications, silver NPs (Ag NPs) in wound healing and burn treatment and Ag-coated catheters to prevent hospital-acquired infections.14,33,65

The SEM micrographs (Fig. S1) reveal pronounced, concentration-dependent alterations in the morphology of E. coli and P. aeruginosa following Ag NPs exposure. In the untreated controls, both bacterial species display intact cell walls with smooth surfaces and well-defined shapes, characteristic of healthy cells. Upon treatment with 50 µg mL−1 Ag NPs, early signs of structural stress become apparent, including surface roughening, localized depressions, and partial deformation of the bacterial envelope.

At the higher concentration of 100 µg mL−1, severe cell damage is evident in both strains. Cells appear collapsed, wrinkled, and fragmented, with clear signs of membrane rupture (highlighted by green arrows), leading to leakage of intracellular contents and the presence of cellular debris. Aggregates of Ag NPs are visible in close association with damaged cells, suggesting strong nanoparticle adhesion to the bacterial surface. These morphological disruptions are consistent with a mechanism involving direct physical interaction of Ag NPs with the cell membrane, destabilization of the cell wall, and potential induction of oxidative stress through reactive oxygen species (ROS) generation, ultimately resulting in cell death.

10.2 Selenium

Selenium is an essential trace element involved in antioxidant defense and immune regulation. The antioxidant mechanism are acts as a cofactor in glutathione peroxidase, neutralizes hydrogen peroxide and lipid peroxides, and modulates ROS production in cells. For the applications, selenium NPs (Se NPs) for oxidative stress-related diseases and selenium-based coatings to improve implant biocompatibility.34 The antibacterial activity of Se NPs was evaluated against Escherichia coli, Bacillus cereus, and Staphylococcus aureus at three different concentrations (50, 75, and 100 µL). The inhibition zone diameters increased with increasing nanoparticle concentration for all tested strains, indicating a clear dose-dependent antibacterial effect (see Fig. 10).
image file: d6na00329j-f10.tif
Fig. 10 MICs of Se NPs and against bacterial pathogens.

At the lowest concentration tested (50 µL), S. aureus exhibited the largest inhibition zone (37 mm), followed by B. cereus (13 mm) and E. coli (11 mm). This suggests that Gram-positive S. aureus is the most susceptible to Se NPs, while Gram-negative E. coli is the least sensitive at this concentration.

At 75 µL, inhibition zones increased to 46 mm (S. aureus), 24 mm (B. cereus), and 19 mm (E. coli). The increase in inhibition zone size was more pronounced for B. cereus and E. coli, indicating enhanced efficacy with higher Se NPs concentrations.

At the highest concentration tested (100 µL), S. aureus maintained the highest inhibition zone (51 mm), followed by B. cereus (33 mm) and E. coli (25 mm). The results confirm that Se NPs exhibit strong antibacterial properties, with greater efficacy against Gram-positive bacteria compared to Gram-negative strains, likely due to differences in cell wall structure and permeability.

In summary, Se NPs demonstrate significant dose-dependent antibacterial activity, with S. aureus being the most sensitive strain. These findings support the potential application of Se NPs as effective antimicrobial agents, particularly against Gram-positive pathogens.

10.3 Copper

Copper exhibits both pro-oxidant and antimicrobial activities, making it suitable for wound care and antimicrobial surfaces. The antibacterial mechanism are catalyzes Fenton-like reactions to generate ROS, and disrupts bacterial membranes via direct ion interaction. For the applications, copper NPs for wound healing gels and Cu coatings for antifouling and biofilm prevention in medical devices.17,18,66

The SEM analysis provides direct evidence of the antimicrobial activity of Cu NPs against E. coli. As can be seen Fig. S2, in the control sample, cells preserved their typical rod-shaped morphology with smooth and intact surfaces, reflecting normal cell wall integrity. However, upon exposure to Cu NPs, the bacterial cells exhibited severe structural alterations, including cell wall deformation, shrinkage, and surface collapse.

These morphological damages strongly suggest that Cu NPs compromise membrane integrity, leading to leakage of intracellular constituents and eventual cell death. Such effects are consistent with the proposed mechanism of Cu NPs antimicrobial activity, involving both physical disruption of the bacterial envelope and oxidative stress-mediated cytotoxicity.

10.4 Titanium

Titanium is extensively used in orthopaedic and dental implants due to its excellent biocompatibility and corrosion resistance. The antibacterial mechanism are photocatalytic generation of ROS by TiO2 under UV or visible light and surface modification with TiO2 nanotubes enhances bactericidal activity. For the applications, Titanium-based implants with antibacterial and Osseo integrative coatings and TiO2 NPs in photodynamic antimicrobial therapy.22,67

The antibacterial activity of TiO2 NPs combined with amoxicillin was evaluated against E. coli and S. aureus, as shown in Fig. 11.


image file: d6na00329j-f11.tif
Fig. 11 The antibacterial activity of TiO2 NPs with amoxicillin against E. coli, and (B) S. aureus.

The results reveal that the inhibition zone diameter increases with the concentration of TiO2 NPs, confirming a dose-dependent antibacterial effect.

At 400 µg mL−1, the inhibition zones were 10.3 mm for E. coli and 11.3 mm for S. aureus. When the concentration increased to 600 µg mL−1, the inhibition zones expanded to 11.3 mm (E. coli) and 12.6 mm (S. aureus). At the highest tested concentration (1000 µg mL−1), E. coli reached an inhibition zone of 11.6 mm, while S. aureus showed the maximum inhibition zone of 13.3 mm. These findings demonstrate that TiO2 NPs exhibit higher antibacterial activity against Gram-positive S. aureus compared to Gram-negative E. coli. This difference can be attributed to structural variations in bacterial cell walls; the thick peptidoglycan layer of S. aureus is more susceptible to disruption by ROS generated by TiO2 NPs, while the outer lipopolysaccharide barrier in E. coli offers partial protection.

Overall, the synergistic effect of TiO2 NPs with amoxicillin significantly enhances antibacterial performance in a concentration-dependent manner, with greater efficacy observed against S. aureus.

11 Metal oxides for antioxidant and antibacterial activities

Metal oxides provide improved stability, controlled ion release, and tunable surface properties for medical applications such as AgO have a highly effective against Gram-positive and Gram-negative bacteria, often used in slow-release wound dressings. SeO2 exhibits redox cycling and mimics enzymatic antioxidant pathways. CuO induces oxidative stress in bacteria, effective in biofilm disruption. TiO2 offers ROS generation for antibacterial activity and UV-triggered antioxidant responses.39,40,68,69

NPs with high antioxidant activity (CeO2) tend to have moderate antibacterial properties, whereas those with strong antibacterial activity (Ag2O, ZnO, CuO) generally exhibit weaker antioxidant effects (see Table 3). This suggests that the biomedical application of metal oxide NPs can be tailored by selecting materials based on the desired therapeutic function whether antioxidant defense, antimicrobial treatment, or dual-purpose hybrid systems.

Table 3 Comparative overview of metal oxide NPs for antioxidant and antibacterial activities
Metal oxide NPs Antioxidant activity Antibacterial activity Mechanism of action Ref.
TiO2 Moderate radical scavenging (DPPH, ABTS); photocatalytic ROS modulation Effective against E. coli and S. aureus; higher under UV light ROS generation, disruption of membranes, protein/DNA interactions 70
ZnO Strong free radical scavenging; high antioxidant index Broad-spectrum activity; effective against multidrug-resistant bacteria ROS production, Zn2+ ion release, cell wall penetration 70 and 71
72
73
CuO Hydroxyl and superoxide radical scavenging Strong activity against E. coli, S. aureus, P. aeruginosa Lipid peroxidation, Cu2+ release, oxidative stress 74
75
CeO2 Excellent antioxidant (SOD- & CAT-mimetic activity) via Ce3+/Ce4+ redox cycling Moderate antibacterial, more effective on Gram-positive bacteria ROS scavenging (antioxidant); surface redox and membrane disruption (antibacterial) 76
77
78
79
Fe3O4 Moderate radical scavenging capacity Limited antibacterial activity unless surface-functionalized ROS generation under chemical/magnetic stimulation 80
81
82
MgO Mild antioxidant behavior Strong antibacterial, especially against Gram-negative bacteria Electrostatic binding, ROS release, alkaline stress 83
84
85
86
Ag2O Weak antioxidant capacity; often enhanced when doped Very strong antibacterial and antifungal action Ag+ release, ROS production, protein/enzyme inactivation 74
87
88
89
90


11.1 Antioxidant activities

NPs have gained significant attention in the field of antioxidants due to their unique properties and effectiveness in scavenging free radicals. Among these, CeO2 NPs are highlighted for their exceptional antioxidant capabilities. This is attributed to their ability to cycle between the Ce3+ and Ce4+ oxidation states, simulating the function of natural antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT). Consequently, CeO2 NPs display remarkable radical-scavenging efficiency. ZnO NPs also exhibit strong antioxidant properties, characterized by their high ability to scavenge free radicals and a considerable antioxidant index, making them effective against oxidative stress.

In contrast, TiO2 and Fe3O4 NPs show a moderate antioxidant effect. TiO2 NPs utilizes photocatalytic mechanisms to modulate ROS, while Fe3O4 NPs activate under specific conditions, either chemically or magnetically, to exhibit antioxidant behavior. MgO NPs and CuO NPs present mild to moderate radical scavenging capabilities, with CuO NPs being particularly effective against hydroxyl and superoxide radicals. Ag2O NPs demonstrate weak intrinsic antioxidant activity; however, their effectiveness can be improved through techniques such as doping or surface modification. Overall, the wide-ranging antioxidant activities of these NPs suggest their potential applications in various biomedical and environmental fields, highlighting the need for further research into optimizing their use for oxidative stress management.

11.2 Antibacterial activities

This study investigates the antibacterial properties of various metal oxide NPs, focusing on their efficacy against a range of bacterial strains, including multidrug-resistant varieties. It highlights that Ag2O and ZnO NPs stand out as the most potent antibacterial agents, exhibiting broad-spectrum effectiveness. The mechanisms underpinning their antibacterial properties include the generation of ROS, the release of metal ions (silver or zinc), and the inactivation of proteins and enzymes. CuO and MgO NPs are noted for their high antibacterial activity as well, with CuO exhibiting effectiveness against both Gram-negative and Gram-positive bacteria through the induction of oxidative stress and lipid peroxidation. MgO NPs is shown to particularly target Gram-negative bacteria, leveraging electrostatic binding and creating alkaline stress conditions.

TiO2 NPs are mentioned for their moderate antibacterial efficiency, which can be notably amplified under UV irradiation due to photocatalytic effects leading to increased ROS production. CeO2 NPs, while demonstrating strong antioxidant properties, have only moderate effectiveness in combating bacteria, primarily functioning better against Gram-positive ones, indicating a need for a balance between their ROS scavenging ability and direct antibacterial action. Finally, Fe3O4 NPs are identified as the least effective agents in an unmodified state. Their antibacterial capacity significantly improves when combined with surface functionalization, underscoring the importance of chemical modifications in enhancing the efficacy of NPs.

12 Mechanistic insights

The article explores the complex behavior of ROS in antibacterial applications. It highlights how ROS play a dual role: on one hand, excessive ROS generation enhances the effectiveness of certain antibacterial materials such as TiO2, ZnO, CuO, and Ag2O NPs. On the other hand, materials like CeO2 NPs utilize the ability to scavenge ROS to exhibit antioxidant properties. The article also emphasizes the significance of ion release, particularly for metals like Ag+, Zn2+, and Cu2+, explaining that these positively charged ions disrupt essential cellular processes and biomolecules in bacteria, contributing to the bacterial inhibition. Additionally, the content points out that surface charge interactions from materials like MgO and CeO2 NPs also play a role in their antibacterial activity, as do the photocatalytic effects observed in TiO2 NPs, which enable diverse bioactivities. Overall, this study unpacks the multifaceted mechanisms at play when using materials to combat bacterial infections.

13 Conclusion

Transition metal and metal oxide NPs represent a highly versatile and tunable class of nanomaterials with significant potential to address two major biomedical challenges: microbial resistance and oxidative stress-related diseases. This review demonstrates that their biological performance is not intrinsic alone, but strongly governed by physicochemical parameters such as size, morphology, surface charge, and functionalization, which collectively define their interaction with biological systems. Establishing clear structure–activity relationships is therefore essential for the rational design of next-generation nanotherapeutics.

A key insight emerging from this work is the dual and sometimes competing role of reactive oxygen species (ROS). While, enhanced ROS generation underpins strong antibacterial activity, controlled ROS scavenging is critical for antioxidant and cytoprotective functions. This inherent trade-off highlights the importance of engineering multifunctional or hybrid nanomaterials capable of achieving a precise balance between antimicrobial efficacy and biocompatibility.

Significant progress has been made in developing advanced synthesis and surface engineering strategies, particularly green synthesis and biofunctionalization approaches, which improve safety profiles and environmental sustainability. However, major challenges remain, including nanoparticle-induced toxicity, bioaccumulation, variability in biological responses, and the lack of standardized evaluation protocols. In addition, the potential emergence of microbial resistance to metal-based nanomaterials necessitates the development of synergistic strategies, such as nanoparticle–antibiotic combinations and multi-metal systems.

Future research should prioritize the systematic in vivo and long-term toxicity studies, a scalable and reproducible synthesis methods, a smart, stimuli-responsive and targeted nanoplatforms, and a rigorous regulatory framework to facilitate clinical translation. Integrating nanotechnology with biomedical engineering, materials science, and molecular biology will be essential to unlock the full therapeutic potential of these systems.

Overall, this review provides a comprehensive and forward-looking perspective that not only consolidates current knowledge but also defines strategic directions for the development of safe, efficient, and clinically relevant metal-based nanomaterials in modern medicine.

Author contributions

IAMA and ABA were involved in planning and designing the research study. IAMA designed and conducted the experiments, analysed the data, and drafted the manuscript. ABA created the results, drafted the article, corrected errors, aided in the manuscript's preparation, and supervised this work. The paper was written by all authors and their contributions were approved before submission.

Conflicts of interest

There are no conflicts to declare.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Supplementary information (SI) is available. See DOI: https://doi.org/10.1039/d6na00329j.

References

  1. S. Iravani, Green Chem., 2011, 13, 2638 RSC.
  2. M. Rai, A. Yadav and A. Gade, Biotechnol. Adv., 2009, 27, 76–83 CrossRef CAS PubMed.
  3. H. Jiang, L. Li, Z. Li and X. Chu, Biomed. Microdevices, 2024, 26, 12 CrossRef PubMed.
  4. C. Zhu, Z. Diao, Y. Yang, J. Liao, C. Wang, Y. Li, Z. Liang, P. Xu, X. Liu, Q. Zhang, L. Gong, Q. Ma, L. Liang and Z. Lin, J. Nanobiotechnology, 2025, 23, 193 CrossRef CAS PubMed.
  5. S. Gautam, D. K. Das, J. Kaur, A. Kumar, M. Ubaidullah, M. Hasan, K. K. Yadav and R. K. Gupta, Discov. Nano., 2023, 18, 84 Search PubMed.
  6. Y. Li, W. Zhang, J. Niu and Y. Chen, ACS Nano, 2012, 6, 5164–5173 CrossRef CAS PubMed.
  7. H. Zhang and G. Chen, Environ. Sci. Technol., 2009, 43, 2905–2910 CrossRef CAS PubMed.
  8. N. Durán, P. D. Marcato, O. L. Alves, G. I. De Souza and E. Esposito, J. Nanobiotechnology, 2005, 3, 8 CrossRef PubMed.
  9. C. Buzea, I. I. Pacheco and K. Robbie, Biointerphases, 2007, 2, MR17–MR71 CrossRef PubMed.
  10. A. Nel, T. Xia, L. Mädler and N. Li, Science, 2006, 311, 622–627 CrossRef CAS PubMed.
  11. H. Kaur, G. C. Mohanta, V. Gupta, D. Kukkar and S. Tyagi, J. Drug Deliv. Sci. Technol., 2017, 41, 106–112 CrossRef CAS.
  12. J. Saxena, A. Singh and A. Jyoti, Nanobiotechnology: Principles and Applications, BENTHAM SCIENCE PUBLISHERS, 2023, pp. 134–156. Search PubMed.
  13. P. Chowdhury, A. Roy and S. Ghosh, Small, 2025, 21(38), e06450 CrossRef CAS PubMed.
  14. E. O. Mikhailova, Antibiotics, 2024, 14, 5 CrossRef PubMed.
  15. J. A. Ansari, J. A. Malik, S. Ahmed, M. Manzoor, N. Ahemad and S. Anwar, Mol. Biol. Rep., 2024, 51, 688 CrossRef CAS PubMed.
  16. X. Qin, Z. Wang, J. Lai, Y. Liang and K. Qian, Nanomaterials, 2025, 15, 301 CrossRef CAS PubMed.
  17. Q. Wei, Y. Pan, Z. Zhang, S. Yan and Z. Li, Chem. Eng. J., 2024, 483, 149040 CrossRef CAS.
  18. S. V. Gudkov, D. E. Burmistrov, P. A. Fomina, S. Z. Validov and V. A. Kozlov, Int. J. Mol. Sci., 2024, 25, 11563 CrossRef CAS PubMed.
  19. L. Näf, I. Miescher, L. Pfuderer, T. A. Schweizer, D. Brunner, J. Dürig, O. Gröninger, J. Rieber, G. Meier-Buergisser, K. Spanaus, M. Calcagni, P. P. Bosshard, Y. Achermann, W. J. Stark and J. Buschmann, Heliyon, 2024, 10, e27267 CrossRef PubMed.
  20. A. G. Kaningini, T. Motlhalamme, G. K. More, K. C. Mohale and M. Maaza, Heliyon, 2023, 9, e15265 CrossRef CAS PubMed.
  21. A. M. Shehabeldine, B. M. Badr, F. M. Elkady, T. Watanabe, M. A. Abdel-Maksoud, A. M. Alamri, S. Alrokayan and A. M. Abdelaziz, Medicina, 2025, 61, 515 CrossRef PubMed.
  22. A. Ghareeb, A. Fouda, R. M. Kishk and W. M. El Kazzaz, Sci. Rep., 2025, 15, 20244 CrossRef CAS PubMed.
  23. Z. Guo, H. Liu, W. Wang, Z. Hu, X. Li, H. Chen, K. Wang, Z. Li, C. Yuan and X. Ge, Biomimetics, 2024, 9, 656 CrossRef CAS PubMed.
  24. L. Wang, C. Hu and L. Shao, Int. J. Nanomed., 2017, 12, 1227–1249 CrossRef CAS PubMed.
  25. J. Huang, Q. Li, D. Sun, Y. Lu, Y. Su, X. Yang, H. Wang, Y. Wang, W. Shao, N. He, J. Hong and C. Chen, Nanotechnology, 2007, 18, 105104 CrossRef.
  26. S. Pal, Y. K. Tak and J. M. Song, Appl. Environ. Microbiol., 2007, 73, 1712–1720 CrossRef CAS PubMed.
  27. T. D. Andreeva, S. D. Petrova, K. Mladenova, V. Moskova-Doumanova, T. Topouzova-Hristova, Y. Petseva, N. Mladenov, K. Balashev, Z. Lalchev and J. A. Doumanov, Colloids Surf., B, 2018, 161, 192–199 CrossRef CAS PubMed.
  28. T. Xia, M. Kovochich, J. Brant, M. Hotze, J. Sempf, T. Oberley, C. Sioutas, J. I. Yeh, M. R. Wiesner and A. E. Nel, Nano Lett., 2006, 6, 1794–1807 CrossRef CAS PubMed.
  29. E.-J. Park, J. Yi, K.-H. Chung, D.-Y. Ryu, J. Choi and K. Park, Toxicol. Lett., 2008, 180, 222–229 CrossRef CAS PubMed.
  30. A. Gholami, M. Mohkam, S. Soleimanian, M. Sadraeian and A. Lauto, Microsyst. Nanoeng., 2024, 10, 113 CrossRef CAS PubMed.
  31. Y. N. Slavin, J. Asnis, U. O. Häfeli and H. Bach, J. Nanobiotechnology, 2017, 15, 65 CrossRef PubMed.
  32. I. A. Mohammed Ali and A. Ben Ahmed, in Deep Science Publishing, Deep Science Publishing, 2025 Search PubMed.
  33. I. A. M. Ali, A. Ben Ahmed and H. I. Al-Ahmed, Sci. Rep., 2023, 13, 2256 CrossRef CAS PubMed.
  34. I. A. Mohammed Ali, H. I. AL-Ahmed and A. Ben Ahmed, Appl. Sci., 2023, 13, 728 CrossRef CAS.
  35. R. F. Hamarawf, RSC Adv., 2024, 14, 9080–9098 RSC.
  36. A. M. Khudhair and A. Ben Ahmed, Chin. J. Phys., 2025, 95, 674–684 CrossRef CAS.
  37. A. M. Khudhair, A. Ben Ahmed, F. N. Ajeel and M. H. Mohammed, Nano-Struct. Nano-Objects, 2024, 38, 101135 CrossRef CAS.
  38. A. M. Khudhair, I. Dhouib, A. Ben Ahmed, F. N. Ajeel and B. Khemakhem, Chin. J. Phys., 2025, 97, 827–838 CrossRef CAS.
  39. G. M. Abdelghani, A. Ben Ahmed and A. B. Al-Zubaidi, Sci. Rep., 2022, 12, 20016 CrossRef CAS PubMed.
  40. G. Mahmood Abdelghani, A. Basim Al-Zubaidi and A. Ben Ahmed, J. Saudi Chem. Soc., 2023, 27, 101623 CrossRef CAS.
  41. G. Mahmood Abdelghani, A. Ben Ahmed and A. Basim Al-Zubaidi, J. Electroceram., 2023, 51, 179–191 CrossRef CAS.
  42. M. Valko, D. Leibfritz, J. Moncol, M. T. D. Cronin, M. Mazur and J. Telser, Int. J. Biochem. Cell Biol., 2007, 39, 44–84 CrossRef CAS PubMed.
  43. G. Yin, Y. Wang and Q. Yuan, J. Nanoparticle Res., 2018, 20, 208 CrossRef.
  44. M. S. Lord, J. F. Berret, S. Singh, A. Vinu and A. S. Karakoti, Small, 2021, 17(51), 2102342 CrossRef CAS PubMed.
  45. B. Liu, X. Zhang, G. Xiao and Y. Lu, Mater. Sci. Eng., C, 2015, 47, 97–104 CrossRef CAS PubMed.
  46. L. Luo, W. Huang, J. Zhang, Y. Yu and T. Sun, ACS Appl. Nano Mater., 2024, 7, 2529–2545 CrossRef CAS.
  47. A. Arora, E. Lashani and R. J. Turner, Microb. Biotechnol., 2024, 17(8), e14549 CrossRef CAS PubMed.
  48. T. J. Abdullah, M. Atif, S. Khalid, K. Metwally, G. Yahya, M. Moisa and D. S. Cavalu, Int. J. Mol. Sci., 2024, 25, 8915 CrossRef CAS PubMed.
  49. A. S. Rodrigues, J. G. S. Batista, M. Á. V. Rodrigues, V. C. Thipe, L. A. R. Minarini, P. S. Lopes and A. B. Lugão, Front. Microbiol., 2024, 15, 1440065 CrossRef CAS PubMed.
  50. A. Abd-El-Aziz, J. Li, M. M. G. Fouda, C. M. Sharaby, X. Zhang, N. Ma, S. N. Agathos and A. S. Abd-El-Aziz, Appl. Mater. Today, 2024, 40, 102335 CrossRef.
  51. P. Monika, R. H. Krishna, A. B. Baliga, K. Ravisagar, R. S. Roy, K. C. Lalitha and S. G. Kumar, Hybrid Adv., 2025, 11, 100522 Search PubMed.
  52. M. Babonaitė, V. Dedonytė, E. Striogaitė and J. R. Lazutka, Mutat. Res., Genet. Toxicol. Environ. Mutagen., 2025, 907, 503888 CrossRef PubMed.
  53. M. Muhaimin, A. Y. Chaerunisaa, M. K. Dewi, A. Khatib and A. Hazrina, Pharmaceuticals, 2025, 18, 703 CrossRef CAS PubMed.
  54. C. Li, J. Liu, Q. Zhang, X. Tang, Y. Liu, A. Cao and H. Wang, Environ. Toxicol., 2025, 40, 802–816 CrossRef CAS PubMed.
  55. N. Zubair, R. M. S. Al-Oqaili, M. J. Yousaf, A. Siddique, F. A. Awwad, E. A. A. Ismail, F. Shams, A. Aldhahrani, N. Itrat, F. Ali, D. P. Rao, H. Khalid, F. Ali, F. A. Al-Salmi, M. A. Alenezi, H. I. Thalib and J. H. Timraz, Sci. Rep., 2025, 15, 45186 CrossRef CAS PubMed.
  56. M. Shafiee, Z. Sabouri, A. Jalili and M. Darroudi, J. Ind. Eng. Chem., 2025, 147, 535–544 Search PubMed.
  57. W. Chen, Y. Jia, Z. Peng, R. Tian and C. Lu, ACS Appl. Mater. Interfaces, 2025, 17, 68674–68683 CrossRef CAS PubMed.
  58. K. Chen, X. Yuan, Z. Tian, M. Zou, Y. Yuan, Z. Chen, Q. Zhang, Y. Zhang, X. Jin, T. Wu, R. Shahbazian-Yassar and G. Liu, Nat. Mater., 2025, 24, 835–842 CrossRef CAS PubMed.
  59. J. Galhano, J. L. Capelo-Martinez, J. Lorenzo, C. Lodeiro and E. Oliveira, ACS Nano, 2025, 19, 31301–31330 CrossRef CAS PubMed.
  60. R. Deng, X. Liu, J. Huang, Y. Wang, D. Chen, C. Wang, K. W. Lai, C. Mao, G. Qian, Y. Zheng and S. Wu, Adv. Funct. Mater., 2025, 35(34), 2500256 CrossRef CAS.
  61. C. V. Vivas, G. B. M. Teobaldo, M. P. Cortez, S. H. Toma, J. J. dos Santos, L. Cartagena, C. L. P. de Oliveira, I. M. Cuccovia, K. Araki, A. C. Bloise and A. M. Alencar, Silicon, 2025, 17, 4377–4394 CrossRef CAS.
  62. R. S. Al-Habeeb, J. Drug Deliv. Sci. Technol., 2026, 115, 107828 CrossRef CAS.
  63. B. S. Adeleke, O. M. Olowe, M. S. Ayilara, O. A. Fasusi, O. P. Omotayo, A. E. Fadiji, D. C. Onwudiwe and O. O. Babalola, Heliyon, 2024, 10, e39636 CrossRef CAS PubMed.
  64. L. Ye, Z. Cao, X. Liu, Z. Cui, Z. Li, Y. Liang, S. Zhu and S. Wu, J. Alloys Compd., 2022, 904, 164091 CrossRef CAS.
  65. S. S. Mohammed Ameen and K. M. Omer, ACS Appl. Nano Mater., 2024, 7(17), 20793–20803 CrossRef CAS.
  66. S. M. Botsa, R. Dharmasoth and K. Basavaiah, Curr. Nanosci., 2018, 15, 209–213 CrossRef.
  67. N. Masahashi, Y. Mori and H. Inoue, Int. Mater. Rev., 2025, 70(6), 465–496 CrossRef CAS.
  68. L. Ladani and M. Palmieri, Metals, 2024, 14, 1039 CrossRef CAS.
  69. I. El-Habib, H. Maatouk, A. Lemarchand, S. Dine, A. Roynette, C. Mielcarek, M. Traoré and R. Azouani, J. Funct. Biomater., 2024, 15, 195 CrossRef CAS PubMed.
  70. N. Sondezi, Z. Njengele-Tetyana, K. P. Matabola and T. A. Makhetha, ACS Omega, 2024, 9, 15959–15970 CrossRef CAS PubMed.
  71. D. Thapliyal, G. D. Verros and R. K. Arya, Polymers, 2025, 17, 247 CrossRef CAS PubMed.
  72. N. Pangprasit, A. Kongkaew, D. Saipinta, S. Pikulkaew, M. Intanon, W. Suriyasathaporn and W. Chaisri, Pharmaceutics, 2025, 17, 209 CrossRef CAS PubMed.
  73. J. A. Sanchez, L. Materon, J. G. Parsons and M. Alcoutlabi, Appl. Sci., 2024, 14, 6274 CrossRef CAS.
  74. A. Hossein Mohammadi, A. Sobhani-Nasab, M. Nejati, S. Hadi, M. Behjati, I. Mirzaii-Dizgah, A. Moradi Hasan-Abad and M. Karami, Inorg. Chem. Commun., 2023, 149, 110404 CrossRef CAS.
  75. A. A. Abed, M. H. Hassouni and H. A. Banimuslem, AIP Conf. Proc., 2025, 3282, 050061 CrossRef.
  76. H. Zheng, J. Tang, Y. Wei, X. Deng, Y. Zhang, X. Ma, X. Jiang, Z. P. Xu and H. Liao, Particuology, 2024, 93, 264–283 CrossRef CAS.
  77. O. L. Pop, A. Mesaros, D. C. Vodnar, R. Suharoschi, F. Tăbăran, L. Mageruşan, I. S. Tódor, Z. Diaconeasa, A. Balint, L. Ciontea and C. Socaciu, Nanomaterials, 2020, 10, 1614 CrossRef CAS PubMed.
  78. A. Fauzia, M. A. Khan, M. Chaman and A. Azam, Sci. Rep., 2024, 14, 6606 CrossRef PubMed.
  79. M. Mohajeri, R. Momenai, S. Karami-Mohajeri, M. Ohadi and M. A. Raeisi Estabragh, Results Chem., 2025, 15, 102302 CrossRef CAS.
  80. G. Prozorova, A. Emel’yanov, A. Ivanova, T. Semenova, T. Fadeeva, A. Nevezhina, S. Korzhova and A. Pozdnyakov, Nanoscale, 2025, 17, 1458–1472 RSC.
  81. U. Y. Suharyadi, M. S. Widodo, A. R. Faqih, H. Suryanto and N. R. Caesar, J. Hazard. Mater. Adv., 2025, 18, 100674 CAS.
  82. S. Gökdağ, F. Caf, F. Doğaner, B. Kaya and G. Aykutoğlu, Plasmonics, 2025, 20, 7527–7545 CrossRef.
  83. W. M. Girma, M. S. Aragie, B. A. Berehe and A. H. Assen, Mater. Adv., 2025, 6, 4003–4015 RSC.
  84. B. Hernández-Figueroa, G. Herrera-Pérez, J. S. Uribe-Chavira, A. Luna-Velasco, A. Castillo-González, B. Sánchez-Ramírez, C. A. Ramírez-Valdespino, M. R. Peralta-Pérez, D. E. Salas-Leiva, E. A. Espinoza-Sánchez and J. S. Salas-Leiva, Appl. Surf. Sci. Adv., 2025, 28, 100797 CrossRef.
  85. K. Ramaprabha, P. Saravanan, R. Rajeshkannan and S. V. Kumar, Sustain. Chem. One World, 2025, 5, 100048 CrossRef.
  86. H. T. Sim, M. Gençaslan and M. Merdan, Discov. Appl. Sci., 2024, 6, 577 CrossRef CAS.
  87. S. Liga, R. Vodă, L. Lupa, E.-A. Moacă, D. Muntean, L. Barbu-Tudoran, M. Suciu, V. Socoliuc and F. Péter, J. Funct. Biomater., 2025, 16, 258 CrossRef CAS PubMed.
  88. T. J. Masho, M. M. Ayane, G. N. Endale, S. H. Adula, Y. D. Negasa, B. W. Likasa, T. S. Mudda, G. K. Negari, H. C. Amante and S. M. Jida, Results Chem., 2025, 13, 101919 CrossRef CAS.
  89. U. Pradhan, J. P. Prajapati, P. Majhi, D. Sahu, R. K. Singh, S. Mallick and A. K. Shukla, Nanoscale Adv., 2025, 7, 3732–3745 RSC.
  90. M. G. S. S. Al-Asbahi, B. A. Al-Ofiri, F. A. A. Saad, A. Alnehia and M. Hadi, J. Mater. Sci. Mater. Med., 2025, 36, 19 CrossRef CAS PubMed.

This journal is © The Royal Society of Chemistry 2026
Click here to see how this site uses Cookies. View our privacy policy here.